World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
39586
World Ranking
7947
National Ranking
4133

Overview

Julie Teruya-Feldstein is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research predominantly focuses on medicine, with significant contributions in oncology, pathology and forensic medicine, hematology, genetics, and immunology.

Their work covers a variety of topics, including:

  • Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Viral-associated cancers and disorders
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction

Julie Teruya-Feldstein has published extensively in several venues. Frequent publication venues include:

  • Blood
  • Blood Advances
  • Nature Medicine
  • Proceedings of the National Academy of Sciences
  • Cancer Discovery

Some of the recent papers authored or co-authored by Julie Teruya-Feldstein are:

  • "Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy", 2021, published in Nature Medicine
  • "Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma", 2021, published in Proceedings of the National Academy of Sciences
  • "Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor-Mutant Neoplasms", 2021, published in Cancer Discovery
  • "NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss", 2022, published in EMBO Reports
  • "Atypical lymphocyte morphology in SARS-CoV-2 infection", 2020, published in Pathology - Research and Practice

Frequent collaborators with Julie Teruya-Feldstein include:

  • Christian Salib (8 joint publications)
  • Siraj M. El Jamal (5 joint publications)
  • Vesna Najfeld (5 joint publications)
  • Sundar Jagannath (4 joint publications)
  • Samir Parekh (4 joint publications)

Best Publications

  • Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

    Li Ma;Julie Teruya-Feldstein;Robert A. Weinberg

  • Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

    Arkaitz Carracedo;Li Ma;Li Ma;Li Ma;Julie Teruya-Feldstein;Federico Rojo

  • miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis

    Li Ma;Jennifer Young;Harsha Prabhala;Elizabeth Pan

  • Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

    Li Ma;Ferenc Reinhardt;Elizabeth Pan;Jürgen Soutschek

  • SIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HIF1α Destabilization

    Lydia W.S. Finley;Arkaitz Carracedo;Jaewon Lee;Amanda Souza

  • Ubiquitination regulates PTEN nuclear import and tumor suppression

    Lloyd C. Trotman;Xinjiang Wang;Andrea Alimonti;Zhenbang Chen

  • Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice

    Rocío Sotillo;Eva Hernando;Elena Díaz-Rodríguez;Julie Teruya-Feldstein

  • p63 Expression Profiles in Human Normal and Tumor Tissues

    Charles J. Di Como;Marshall J. Urist;Irina Babayan;Marija Drobnjak

  • PML targeting eradicates quiescent leukaemia-initiating cells

    Keisuke Ito;Rosa Bernardi;Alessandro Morotti;Sahoko Matsuoka

  • RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

    Andrew L Wolfe;Kamini Singh;Yi Zhong;Philipp Drewe

  • The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.

    Min Sup Song;Leonardo Salmena;Arkaitz Carracedo;Ainara Egia

  • Dissecting eIF4E action in tumorigenesis

    Hans-Guido Wendel;Ricardo L.A. Silva;Abba Malina;John R. Mills

  • Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants

    Michael T. Hemann;Anka Bric;Julie Teruya-Feldstein;Andreas Herbst

  • Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts

    Aruna Kode;John S. Manavalan;Ioanna Mosialou;Govind Bhagat

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

    Christina Gewinner;Zhigang C. Wang;Andrea Richardson;Julie Teruya-Feldstein

  • Role of the proto-oncogene Pokemon in cellular transformation and ARF repression

    Takahiro Maeda;Robin M. Hobbs;Taha Merghoub;Ilhem Guernah

  • Skp2 targeting suppresses tumorigenesis by Arf-p53- independent cellular senescence

    Hui Kuan Lin;Zhenbang Chen;Zhenbang Chen;Zhenbang Chen;Guocan Wang;Caterina Nardella;Caterina Nardella

  • Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

    Ferenc Reinhardt;Elizabeth Pan;Jürgen Soutschek;Balkrishen Bhat

  • Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (Nature (2007) 449, (682-688))

    Li Ma;Julie Teruya-Feldstein;Robert A. Weinberg

Frequent Co-Authors

Pier Paolo Pandolfi
Pier Paolo Pandolfi Beth Israel Deaconess Medical Center
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Elaine S. Jaffe
Elaine S. Jaffe National Institutes of Health
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Giovanna Tosato
Giovanna Tosato National Institutes of Health
Stephen D. Nimer
Stephen D. Nimer University of Miami
Ross L. Levine
Ross L. Levine Memorial Sloan Kettering Cancer Center
Carlos Cordon-Cardo
Carlos Cordon-Cardo Icahn School of Medicine at Mount Sinai
Madhav V. Dhodapkar
Madhav V. Dhodapkar Emory University
Mark Raffeld
Mark Raffeld National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary online degrees in the healthcare field can help expand your career opportunities in medicine. Many students consider an online mha programs affordable option, which prepares graduates for leadership roles in healthcare management and administration.

For registered nurses looking to advance their practice and impact patient care, cheap dnp online programs offer a flexible way to earn a Doctor of Nursing Practice without stepping away from current work commitments.

Those interested in pharmacy can pursue pharm d online programs, which open doors to advanced clinical and research roles in the pharmaceutical field, all with the convenience of distance learning.

Additionally, individuals who wish to work in medical data and technology can benefit from rhit programs online. These programs train you in managing health records and information systems, a sector with rapidly growing demand.

By considering these related online degrees, students and professionals can find flexible education options that align with diverse career pathways in the healthcare sector.

Best Scientists Citing Julie Teruya-Feldstein

Trending Scientists